• Updated Phase Ib/IIa Brainshuttle™ AD study data for trontinemab demonstrating rapid amyloid removal dynamics and changes in key biomarkers 
• Phase III PrevenTRON study design specifics for trontinemab in preclinical Alzheimer’s disease, which has commenced enrolment
• Phase II TARBELA-AD study design for the investigational oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer’s disease, representing a novel mechanism of action targeting neuroinflammation
• Global clinical and health economic data on the Elecsys® pTau217 and Elecsys pTau181 blood tests supporting accessible, timely diagnosis

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.